189998-53-6

Upstream product

• 108-24-7 acetic anhydride 

Downstream Products

• 160963-11-1 2,6-dichloro-9-<5-O-(tert-butyldiphenylsilyl)-2,3-dideoxy-4-thio-β-L-ribofuranosyl>purine 
• 173009-34-2 2,6-dichloro-9-<5-O-(tert-butyldiphenylsilyl)-2,3-dideoxy-4-thio-α-L-ribofuranosyl>purine 
• 160853-26-9 2,6-Diazido-9-[(2S,5R)-5-(tert-butyl-diphenyl-silanyloxymethyl)-tetrahydro-thiophen-2-yl]-9H-purine 
• 173009-41-1 2-chloro-6-amino-9-<5-O-(tert-butyldiphenylsilyl)-2,3-dideoxy-4-thio-α-L-ribofuranosyl>purine 
• 173009-37-5 2-chloro-6-amino-9-<5-O-(tert-butyldiphenylsilyl)-2,3-dideoxy-4-thio-β-L-ribofuranosyl>purine 
• 173009-42-2 2,6-diamino-9-<5-O-(tert-butyldiphenylsilyl)-2,3-dideoxy-4-thio-α-L-ribofuranosyl>purine 
• 160963-13-3 2,6-diamino-9-<5-O-(tert-butyldiphenylsilyl)-2,3-dideoxy-4-thio-β-L-ribofuranosyl>purine 

Relevant academic research and scientific papers

2-(tert-Butyldimethylsiloxy)thiophene: Application to total syntheses of both enantiomers of 2',3'-dideoxy-4'-thiocytidine

Exploiting novel 2-(tert-butyldimethylsiloxy)thiophene (1, TBSOT) as versatile carbon nucleophile and both enantiomers of glyceraldehyde acetonide as chiral sources, an entry to both enantiomers of anti HIV-active 2',3'-dideoxy-4'-thiocytidine 10 and ent-10 was devised and executed.

L-2',3'-dideoxy nucleoside analogs as anti-hepatitis B (HBV) and anti-HIV agents

The present invention relates to the surprising discovery that certain dideoxynucleoside analogs which contain a dideoxy ribofuranosyl moiety having an L-configuration (as opposed to the naturally occurring D-configuration) exhibit unexpected activity against Hepatitis B virus (HBV). In particular, the compounds according to the present invention show potent inhibition of the replication of the virus in combination with very low toxicity to the host cells (i.e., animal or human tissue). Compounds according to the present invention exhibit primary utility as agents for inhibiting the growth or replication of HBV, HIV and other retroviruses, most preferably HBV. The compound 1-(2,3-dideoxy-beta-L-ribofuranosyl)-5-fluorocytosine is shown to be a potent anti-HIV agent with low toxicity to host cells.

Method for treating HBV infections with L-2',3'-didehydro-dideoxy-5-fluorocytidine

The present invention relates to the surprising discovery that certain dideoxynucleoside analogs which contain a dideoxy ribofuranosyl moiety having an L-configuration (as opposed to the naturally occurring D- configuration) exhibit unexpected activity against Hepatitis B virus (HBV). In particular, the compounds according to the present invention show potent inhibition of the replication of the virus in combination with very low toxicity to the host cells (i.e., animal or human tissue). Compounds according to the present invention exhibit primary utility as agents for inhibiting the growth or replication of HBV, HIV and other retroviruses, most preferably HBV.